Guangdong Jiaying Pharmaceutical Co., Ltd
Simbols: 002198.SZ
SHZ
6.73
CNYTirgus cena šodien
121.8232
P/E koeficients
10.9641
PEG koeficients
3.42B
MRK Cap
- 0.00%
DIV ienesīgums
Guangdong Jiaying Pharmaceutical Co., Ltd (002198-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1231.73 | 334 | 234.1 | 239.4 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 660.9 | 200.5 | 50.3 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 657.68 | 154 | 240.6 | 175.7 | ||||||||||||||||||||
balance-sheet.row.inventory | 347.58 | 84.6 | 82.3 | 73.4 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 5.96 | 1.1 | 0.4 | 1.2 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 2267.86 | 580.2 | 557.4 | 489.7 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 769.11 | 190.4 | 203.7 | 224.2 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 191.46 | 47.2 | 52.4 | 58.3 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 191.46 | 47.2 | 52.4 | 58.3 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | -134.09 | 27.1 | -20.9 | 30.6 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 8.72 | 2.2 | 2.2 | 4.6 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 240.92 | 0.5 | 51.8 | 0 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 1076.11 | 267.4 | 289.2 | 317.7 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 3343.97 | 847.6 | 846.7 | 807.3 | ||||||||||||||||||||
balance-sheet.row.account-payables | 42.13 | 9.2 | 19 | 14.1 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | -2.03 | 0 | 5.8 | 31.1 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 28.03 | 7.5 | 17.2 | 12 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 1.72 | 0.4 | 0.5 | 0.2 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 139.12 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 118.62 | 40.2 | 47.1 | 5.7 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 140.84 | 35.2 | 35.3 | 34.9 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-liab | 315.92 | 84.6 | 118.2 | 122.9 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 54.45 | 27.2 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 2030.04 | 507.5 | 507.5 | 507.5 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 398.09 | 104.6 | 70.3 | 26.3 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 174.76 | 0 | 27.2 | 27.2 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 370.71 | 123.7 | 123.4 | 123.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 3028.05 | 763 | 728.4 | 684.5 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3343.97 | 847.6 | 846.7 | 807.3 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 3028.05 | 763 | 728.4 | 684.5 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3343.97 | - | - | - | ||||||||||||||||||||
Total Investments | 105.91 | 27.1 | 29.4 | 30.6 | ||||||||||||||||||||
balance-sheet.row.total-debt | 5.87 | 0 | 5.8 | 31.1 | ||||||||||||||||||||
balance-sheet.row.net-debt | -564.95 | -133.5 | -178.1 | -208.3 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 27.32 | 43.9 | 1.5 | 19.8 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 18.01 | 25.9 | 28.4 | 28.2 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 2.4 | 1 | -0.6 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -2.4 | -1 | 0.6 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 116.01 | -48.4 | -4.8 | 38.8 | |||||||||||||||||||
cash-flows.row.account-receivables | 118.37 | -86.5 | 9.6 | 9 | |||||||||||||||||||
cash-flows.row.inventory | -2.36 | -8.4 | -0.8 | 2.5 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | 44.1 | -14.7 | 27.9 | |||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 2.4 | 1 | -0.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -48.06 | 5.7 | 26.7 | 10 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 113.28 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -12.26 | -2.7 | -2.3 | -11.7 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 141.97 | 0.1 | 0 | 0 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -0.1 | 0 | 0 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | -126.83 | 1.6 | 32.5 | 18.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -180 | -49.9 | 25.1 | -25 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -176.93 | -51 | 55.2 | -18.2 | |||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -31.1 | -15 | -135 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -0.5 | -1 | -3.8 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 31.1 | 55 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -31.6 | 15.1 | -83.8 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | -64.89 | -55.4 | 122.1 | -5.1 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 567.95 | 183.9 | 239.3 | 117.2 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 632.85 | 239.3 | 117.2 | 122.3 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 113.28 | 27.2 | 51.8 | 96.9 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -12.26 | -2.7 | -2.3 | -11.7 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 101.02 | 24.4 | 49.5 | 85.2 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 499.15 | 533.2 | 659.2 | 574.7 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 184.54 | 185.5 | 228.5 | 141.9 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 314.61 | 347.7 | 430.7 | 432.8 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 10.47 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 13.37 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 219.49 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | -1.19 | -1.1 | 40.7 | 46.3 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 285.61 | 310.4 | 376 | 403.2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 470.15 | 495.9 | 604.5 | 545.1 | ||||||||||||||||||||
income-statement-row.row.interest-income | 2.17 | 2.1 | 2.3 | 2.6 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0.5 | 1 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 219.49 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0.14 | 2.1 | -2.8 | -27.8 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -1.19 | -1.1 | 40.7 | 46.3 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0.14 | 2.1 | -2.8 | -27.8 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0.5 | 1 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 8.91 | 24.2 | 26.6 | 28.4 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 30.17 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 33.65 | 40.5 | 53.9 | 33.6 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 32.46 | 39.4 | 51.1 | 5.8 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 5.15 | 5.1 | 7.2 | 4.3 | ||||||||||||||||||||
income-statement-row.row.net-income | 27.32 | 34.3 | 43.9 | 1.5 |
Biežāk uzdotie jautājumi
Kas ir Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) kopējie aktīvi?
Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) kopējie aktīvi ir 847563113.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 250417163.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.630.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.199.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.055.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.067.
Kāda ir Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 34320234.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 0.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 310409681.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 118503980.000.